Medicamen Biotech Announces Dividend and Q1 FY27 Results

Medicamen Biotech has declared a final dividend of 10% (Re 1 per equity share) and reported an increase in total revenue and net profit for the quarter ending June 30, 2026.

Reader Takeaway: Dividend approved, financials show growth, but past compliance issues noted.

What just happened

The Board of Directors of Medicamen Biotech Ltd. has approved a final dividend of Re 1 per equity share. The company also noted its financial performance for the quarter ended June 30, 2026. Separately, the board acknowledged a compliance issue related to the Nomination and Remuneration Committee, for which the company paid fines to BSE and NSE.

Why this matters

Shareholders will benefit from the proposed dividend, indicating the company's profitability and commitment to returning value. The financial growth signals operational improvement. However, the past non-compliance, though addressed with fines, highlights governance areas that investors should monitor.

The backstory

For the quarter ended June 30, 2026, Medicamen Biotech reported standalone total revenue of Rs 44.71 crore, up from Rs 38.92 crore in the same period last year. Standalone net profit rose to Rs 2.53 crore from Rs 1.64 crore. On a consolidated basis, total revenue was Rs 48.76 crore, compared to Rs 43.52 crore, and net profit increased to Rs 1.85 crore from Rs 1.60 crore.

The company paid approximately Rs 1.11 lakh each to BSE and NSE in June 2026 for non-compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically concerning the constitution of the Nomination and Remuneration Committee.

What changes now

The company has fixed September 19, 2026, as the record date for the final dividend, which is subject to shareholder approval at the 33rd Annual General Meeting scheduled for September 26, 2026. The board has instructed management to ensure strict adherence to all SEBI and exchange regulations going forward.

Risks to watch

While the company has paid fines for past non-compliance, continued adherence to listing regulations and robust corporate governance practices will be crucial for maintaining investor confidence.

Peer comparison

As of the latest filings, specific peer financial comparisons are not detailed. However, growth in revenue and profit are generally positive indicators within the pharmaceutical sector.

Context metrics (time-bound)

• Dividend: Re 1 per equity share (10%).
• Record Date: September 19, 2026.
• AGM Date: September 26, 2026.
• Q1 FY27 Standalone Revenue: Rs 44.71 crore.
• Q1 FY27 Standalone Profit: Rs 2.53 crore.
• Q1 FY27 Consolidated Revenue: Rs 48.76 crore.
• Q1 FY27 Consolidated Profit: Rs 1.85 crore.
• Compliance Fines Paid: ~Rs 1.11 lakh each to BSE and NSE in June 2026.

What to track next

Investors should monitor the outcome of the AGM and the actual dividend payout. Continued financial performance and sustained compliance with regulatory norms will be key factors to watch.